MOSCOW (Reuters) – Russia has developed a new and promising cure for the new Coronavirus code 19, with the United States and Japan approving its emergency use.
According to details, Russia has approved the use of the antiviral drug Favipervir as a treatment for coronavirus sufferers. Remediators developed by Gilead Science have been found to be effective in treating the virus in various research reports, after which its emergency use in the United States and Japan has been approved.
But Russia has approved the use of the Japanese-made antiviral drug Favipervir, as a treatment for people suffering from the epidemic.
In this regard, the head of RDIF, Karl Dimitrov, said that during the trial, 60% of the 40 patients with Coronavirus were given this drug, and they recovered in 5 days, which is more than other therapies—recovery time reduced by 50%.
Russia is in the final stages of clinical trials of the drug involving 330 patients, with results expected to be released this week.
Russian officials have declared the drug safe and effective for the treatment of COVID 19, which will begin treating Corona patients in Russian hospitals from June 11 and exported to other countries after meeting demand. Will go
It is estimated that more than 423,000 people have been infected with the Coronavirus in Russia so far, while more than 5,000 people have lost their lives.